Browse by category

Xeno Biosciences initiate phase 1b proof-of-concept study for obesity drug candidate XEN-101

Xeno Biosciences has initiated a Phase 1b clinical study designed to provide proof-of-concept weight loss results, along with safety and...

Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG

7 hours ago

Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss

8 hours ago

Racial and ethnic groups face barriers to obtaining OMMs

8 hours ago

Weekly Digest